Cyclobenzaprine/etodolac

Drug Profile

Cyclobenzaprine/etodolac

Alternative Names: Cyclobenzaprine/etodolac - Apsen Farmaceutica

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apsen Farmaceutica
  • Class Dibenzocycloheptenes; Indoleacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Postoperative pain

Most Recent Events

  • 17 Apr 2017 Preclinical trials in Postoperative pain in Brazil (unspecified route) before April 2017 (NCT03127592)
  • 17 Apr 2017 Apsen Farmaceutica plans the phase III FDCETCB-III trial for Postoperative pain (In adults, In the elderly, In volunteers, Combination therapy) (NCT03127592)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top